Solara Industry Brief

<p>Recent regulatory developments have created plenty of confusion about what’s actually happening with peptides. In this episode, we break down the changing regulatory landscape, recent FDA activity involving commonly discussed peptides, and the important differences between FDA approval, compounding eligibility, safety evaluations, and outright prohibition. A clear, practical look at what has changed, what hasn’t, and what medical professionals should be watching next.</p><p><br/></p>